Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Smart insulin pump could ease diabetes management for kidney patients on dialysis

NCT ID NCT07422532

First seen Feb 21, 2026 · Last updated Jun 23, 2026 · Updated 20 times

Summary

This study tests whether an automated insulin delivery system (the Omnipod 5) can help people with type 2 diabetes who are on dialysis achieve better blood sugar control. Half of the 84 participants will use the automated system, while the other half will continue their usual insulin injections. The goal is to see if the device improves glucose levels and quality of life over 12 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guys and St Thomas' Hospitals

    London, United Kingdom

    Contact Email: •••••@•••••

    Contact

  • Hammersmith Hospital

    London, United Kingdom

    Contact Email: •••••@•••••

  • Manchester Royal Infirmary

    Manchester, United Kingdom

    Contact Email: •••••@•••••

  • Royal Derby Hospital

    Derby, United Kingdom

    Contact Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Omnipod 5 automated insulin delivery system

What this could lead to

If it works, this could offer a safer, easier way for people with type 2 diabetes on dialysis to manage their blood sugar without constant finger-prick tests.

What could go wrong

This is a small, early-stage trial with only 84 participants. The device is not yet proven for this specific group, and results may not apply to everyone. There is also a risk of device malfunction or low blood sugar.

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome end stage renal failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.